Physician profile
Athanasios George Marneris
NPI 1467866228
$18,878.06
in general payments reported to CMS, 2019-2025
21 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $218 · 2021: $411 · 2022: $630 · 2023: $1,011 · 2024: $16K · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $2,204 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,000.00 |
| Food and Beverage | $2,203.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $15,905.95 | 2021-2025 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| Alcon Vision LLC | $1,323.85 | 2020-2025 | Centurion, Argos, Ngenuity |
| Mallinckrodt Hospital Products INC. | $180.73 | 2024-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $160.89 | 2019-2021 | |
| Rxsight INC | $139.31 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Allergan, INC. | $139.29 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $130.92 | 2023-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Abbvie INC. | $122.93 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $114.23 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $113.69 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $111.46 | 2022-2025 | Xiidra, Miebo, Lotemax Sm |
| Sight Sciences, INC. | $81.88 | 2020-2024 | Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $68.02 | 2021-2022 | |
| Thea Pharma INC. | $63.26 | 2023-2024 | Iyuzeh |
| Tearlab Corp | $59.96 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $37.91 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Dompe US, INC. | $37.32 | 2021-2024 | Oxervate |
| Ivantis, INC | $27.62 | 2020 | |
| Harrow Eye, LLC | $25.08 | 2025 | Vevye |
| Lkc Technologies, INC. | $19.81 | 2025 | |
| Biotissue Holdings INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Athanasios Marneris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.